Kornitzer Capital Management Inc. KS acquired Previa Health Group, Inc. Decreased stock position in (Nasdaq: PRVA)

Kornitzer Capital Management Inc. KS acquired Previa Health Group, Inc. (Nasdaq: PRVA – RECEIVE Ratings) reduced its holdings by 18.5% in the third quarter, according to its most recent filing with the SEC. The firm held 608,765 shares of the company’s stock after selling 138,155 shares during the period. At the end of the most recent quarter, Kornitzer Capital Management Inc. KS owned approximately 0.55% of Privia Health Group worth $20,735,000.

→ Free eBook: The Ultimate Guide to Investing in the Stock Market (from Vector West)pixel

Other big investors also bought and sold shares of the company recently. Assetmark Inc. increased its holding in the shares of Privia Health Group by 119.4% in the second quarter. After acquiring an additional 486 shares during this period, Assetmark Inc. holds 893 shares of the company’s stock, valued at $26,000. First Horizon Advisors Inc. raised its holding in shares of Privia Health Group to 4,330.4% during the second quarter. After acquiring an additional 996 shares last quarter, First Horizon Advisors Inc. holds 1,019 shares of the company valued at $29,000. Nysa Investment Advisors LLC bought a new position in Privia Health Group in the second quarter worth $46,000. Point72 Hong Kong Limited bought a new position in Privia Health Group in the 1st quarter worth $47,000. Lastly, Ameritas Investment Partners Inc. raised its stake in Privia Health Group to 111.5% in the first quarter. Ameritas Investment Partners Inc. after buying an additional 1,714 shares during the last quarter. now owns 3,251 shares of the company’s stock valued at $87,000. Institutional investors hold 66.83% of the company’s shares.

Privia Health Group stock up 0.6%

Shares of PRVA stock traded up $0.16 during trading hours on Friday, to $25.38. 4,323 shares of the company’s stock were exchanged hands as compared to an average volume of 871,047. Privia Health Group, Inc. has a 52 week low of $17.99 and a 52 week high of $44.64. The firm has a market cap of $2.90 billion, a P/E ratio of -70.05, and a beta of 0.67. The firm’s 50-day moving average is $23.76 and its 200-day moving average is $31.53.

Privia Health Group (NASDAQ: PRVA – Receive Rating) last posted its quarterly earnings data on Thursday, November 10. The company reported earnings per share (EPS) of $0.01 for the quarter. Previa Health Group had a negative net margin of 3.02% and a negative return on equity of 6.82%. The business had revenue of $342.90 million for the quarter, compared to consensus estimates of $323.66 million. On average, equity analysts expect Privia Health Group, Inc. to post -0.26 earnings per share for the current fiscal year.

insider buying and selling

In other news, Director William M. Sullivan sold 6,038 shares of the business’s stock in a transaction on Thursday, Jan. 12. The shares were sold at an average price of $25.02, for a total transaction of 151,070.76. Following the transaction, the Director now owns 5,826,930 shares of the Company’s stock, valued at approximately $145,789,788.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director William M. Sullivan sold 6,038 shares of the stock in a transaction that occurred on Thursday, Jan 12. The stock was sold at an average price of $25.02 for a total value of $151,070.76. Following completion of the transaction, the Director now directly owns 5,826,930 shares in the Company, valued at $145,789,788.60. The sale was disclosed in a document filed with the Securities and Exchange Commission, which is available at this hyperlink. In addition, Major Shareholder Advisors LLC MBD sold 3,186,888 shares of the company’s stock in a transaction on Monday, November 21. Shares were sold at an average price of $22.56, for a total value of $71,896,193.28. Following the completion of the transaction, the insider now directly owns 24,826,071 shares in the company, valued at approximately $560,076,161.76. Disclosure of this sale can be found here. In the last three months, insiders have sold 3,692,525 shares of company stock worth $84,594,181. 57.60% of the stock is owned by insiders.

Wall Street Analysts Weigh In

Several research firms have recently issued reports on PRVA. Truest Financial cut its price objective on shares of Privia Health Group to $41.00 in a report on Thursday, November 17. Stifel Nicolaus initiated coverage on Privia Health Group in a research note on Thursday, December 8. He issued a “Buy” rating and a target price of $28.00 for the company. Canaccord Genuity Group cut its target price on Privia Health Group from $50.00 to $43.00 and set a “buy” rating on the company in a research note on Friday, November 11. Piper Sandler cut its price objective on Privia Health Group to $42.00 in a report on Thursday, November 17. Finally, UBS Group initiated coverage on Privia Health Group in a research report on Thursday, December 8. He issued a “buy” rating and $30.00 target price on the stock. Twelve equity research analysts have rated the stock with a Buy rating, according to MarketBeat.com, Privia Health Group currently has a consensus rating of “Buy” and a consensus price target of $39.46.

Privia Health Group Profile

(get rating)

Privia Health Group, Inc. operates as a national physician-enabled company in the United States. The company collaborates with medical groups, health plans and health systems to optimize physician practices, enhance patient experiences, and reward doctors for providing care in in-person and virtual settings.

see all

Institutional Ownership by Quarter for Privia Health Group (NASDAQ: PRVA)

This instant news alert was generated by descriptive science technology and financial data from MarketBeat to provide readers the fastest and most accurate reporting. This story was reviewed by Marketbeat’s editorial team before publication. Please send any questions or comments about this story to [email protected]

Before you consider Previa Health Group, you may want to hear this.

MarketBeat tracks Wall Street’s top rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified five stocks that top analysts are quietly whispering to their clients to buy, before the broader market catches on… and Privia Health Group wasn’t on the list.

While Privia Health Group currently has a “Buy” rating among analysts, top rated analysts believe these five stocks are a Better Buys.

see five stocks here

The Beginner's Guide To Pot Stock Investing Covers

,

Leave a Comment